Evogene Reports Q3 2026 Results, Advances aGVHD and Fungicide Programs
Evogene highlights progress in two internal development programs targeting acute graft-versus-host disease and novel agricultural fungicides.
Evogene Ltd., the Israel-based computational biology company listed on both Nasdaq and the Tel Aviv Stock Exchange, released its financial results for the third quarter and first nine months of 2026 on Wednesday, pointing to meaningful advances in two internally developed programs.
The company said its drug discovery initiative is making headway in targeting acute graft-versus-host disease, a serious and often life-threatening complication that can arise following stem cell or bone marrow transplants. The program represents one of Evogene's core internal bets on translating its computational platform into clinical-stage assets.
Read more Leverage Shares Launches 2x Long Anthropic ETF as ANT Debuts on Nasdaq →
On the agricultural side, Evogene's subsidiary AgPlenus is advancing a fungicide discovery effort aimed at developing a novel mode of action against Septoria, a fungal pathogen that poses a significant threat to wheat crops globally. A new mechanism of action is considered strategically valuable in agriculture because existing fungicide classes face growing resistance pressure from evolving pathogens.
The dual-front progress underscores Evogene's broader strategy of leveraging its proprietary computational genomics tools — originally developed for crop science — across both human health and agriculture. By pursuing internal programs rather than relying solely on licensing partnerships, the company is working to capture more of the value chain from its core technology.
Full financial figures for the quarter and nine-month period were included in the company's official release. Continue reading at Earnings.